Hologic, Inc. (HOLX)

Market Cap	17.72B
Revenue (ttm)	3.96B
Net Income (ttm)	466.50M
Shares Out	233.38M
EPS (ttm)	1.95
PE Ratio	38.97
Forward PE	18.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,528
Open	75.90
Previous Close	76.10
Day's Range	75.52 - 76.20
52-Week Range	64.02 - 84.28
Beta	1.02
Analysts	Buy
Price Target	85.60 (+12.74%)
Earnings Date	May 2, 2024

About HOLX

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis ass...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX

Financial Performance

In 2023, Hologic's revenue was $4.03 billion, a decrease of -17.12% compared to the previous year's $4.86 billion. Earnings were $456.00 million, a decrease of -64.98%.

Analyst Forecast

According to 10 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $85.6, which is an increase of 12.74% from the latest price.

Price Target

$85.6

(12.74% upside)

Analyst Consensus: Buy